An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Subjects Positive for Carbonic Anhydrase IX (CAIX)

Trial Profile

An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Subjects Positive for Carbonic Anhydrase IX (CAIX)

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs SLC 0111 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors SignalChem Lifesciences
  • Most Recent Events

    • 22 Feb 2018 Status changed from planning to not yet recruiting.
    • 08 Dec 2014 New trial record
    • 04 Dec 2014 This trial is expected to be initiated later in 2015, according to a SignalChem Lifesciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top